03 Profile
Hansard to 4 November 2026 · 31,174 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Eslam Katab
global clinical development manager at Sandoz
press citation on 1 topic since 9 Dec 2025 · last quoted 9 Dec 2025
02 Quoted on · 1 of 29 topics
Eslam Katab: key facts
- Kind of voice
- Sector leader
- Role
- global clinical development manager at Sandoz
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 9 Dec 2025
04 The signal · where Eslam Katab sits on rare diseases
Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
- 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
- 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
- 25=Channa DebruyneSector leaderglobal clinical development lead, late-stage and LCM oncology, at Servier1
- 25=Clara Cali MellaSector leaderdata strategy lead at Bayer1
- 25=Eslam KatabSector leaderglobal clinical development manager at Sandoz1
- 25=Dr Su LwinClinicianSenior Research Fellow at King's College London and Consultant Dermatologist at Guy's and St Thomas'1
- 25=Suma ShankarAcademicChief of the Genomic Medicine Division in the Department of Pediatrics and director of Precision Genomics, professor in the Departments of Pediatrics and Ophthalmology1
Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →
05 On the record · press
What Eslam Katab has said
- clinicaltrialsarena.com1
Where Eslam Katab has been quoted
- 01Utilising real-world data to overcome challenges in rare disease researchclinicaltrialsarena.com · 9 Dec 2025
Verbatim
“AI could be used to enhance the process of leveraging historical real-world data into synthetic control arms so that these are matched on key prognostic factors and propensity weighting can be applied appropriately”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.